Epichem has always been the failsafe to this investment and it is great to see they have had a cash positive quarter BUUUUT MPL1 has been an unmitigated disaster from day 1. This is 2 years of lost time. Patients have not been able to keep the meds down and now they realise the dosage size requires an whole new formulation.
We have gone from liquid to gel caps and now to powder. A bit of foresight could have prevented this imo.
If Roger Aston is too busy to oversee this company then he should resign to make way for someone who has the time.
Still happy to keep this in bottom drawer as I believe MPL1 will be a winner- just need the right people to make this happen.
(John Best performing like a champ though)
Ann: Appendix 4C - Quarterly Report & Company Update - March 2017, page-11
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.3¢ |
Change
-0.008(3.75%) |
Mkt cap ! $95.88M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.0¢ | $55.74K | 284.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 202056 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 63645 | 3 |
View Market Depth
| Last trade - 13.50pm 18/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |